PolarityTE, Inc. (PTE)
After hours:
- Zacks
PolarityTE, Inc. (PTE) Upgraded to Strong Buy: Here's What You Should Know
PolarityTE, Inc. (PTE) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Zacks
PolarityTE, Inc. (PTE) Reports Q1 Loss, Misses Revenue Estimates
PolarityTE, Inc. (PTE) delivered earnings and revenue surprises of -25% and 12.82%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
BioMed Stocks On the Move: Nova Mentis, PolarityTE, Veru, and PharmaDrug; Life Sciences Leaders Report Latest Advances in Regenerative Tissue Technology, Novel Therapeutics for Oncology, COVID, Glaucoma, and Autism
NEW YORK, May 13, 2022 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEO’s of: Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA), PolarityTE, Inc. (NASDAQ: PTE) Veru Inc. (NASDAQ: VERU), and PharmaDrug (OTC: LMLLF) (CSE: PHRX). As the global pharma market surpasses $1.3 trillion dollars (Statista), emerging technologies and healthcare research innovations are unleashing new exponential grow
